Advertisement
Advertisement
AKBA
Akebia Therapeutics, Inc.
0.40
USDSponsored
-0.02
-5.69%
Nov 06, 15:59 UTC -5
Closed
After-Market
0.41
0.00
+0.92%
Akebia Therapeutics, Inc. (AKBA) Earnings
AKBA Earnings Reports
Positive Surprise Ratio
AKBA beat 19 of 44 last estimates.
43%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$37.33M
/-$0.04
Implied change from Q3 26 (Revenue/ EPS)
+1.15%
/-20.00%
Implied change from Q4 25 (Revenue/ EPS)
-35.22%
/-20.00%
Akebia Therapeutics, Inc. earnings per share and revenue
On Nov 05, 2026, AKBA reported earnings of -0.05 USD per share (EPS) for Q3 26, missing the estimate of -0.03 USD, resulting in a -52.41% surprise. Revenue reached 36.90 million, compared to an expected 47.88 million, with a -22.93% difference. The market reacted with a -38.75% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 6 analysts forecast an EPS of -0.04 USD, with revenue projected to reach 37.33 million USD, implying an decrease of -20.00% EPS, and increase of 1.15% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Akebia Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Akebia Therapeutics, Inc. reported EPS of -$0.05, missing estimates by -52.41%, and revenue of $36.90M, -22.93% below expectations.
How did the market react to Akebia Therapeutics, Inc.'s Q3 2026 earnings?
The stock price moved down -38.75%, changed from $0.69 before the earnings release to $0.43 the day after.
When is Akebia Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Akebia Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Akebia Therapeutics, Inc. is expected to report EPS of -$0.04 and revenue of $37.33M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.